Vectus Biosystems Limited

VBS.ASX

Health Care

Medical research and development. Phase I human trials for anti-fibrotic drug VB0004 completed.

Market Data

Price

$0.110

-0.0%
Market Cap

$6.8M

P/E Ratio

-100000.0x

EPS

$-0.026

Div. Yield

0.00%

52-Week Change

-0.6%

Latest Earnings

Half Year Report & Appendix 4D

26 February 2026

Revenue
$0.01
-99.0% YoY
NPAT
-$0.73
-33.0% YoY
EPS
$-0.01

Vectus Biosystems reported a reduced half-year loss of $731,694 (down 33% from $1.1M previously) as the biotech company significantly cut operating costs while pursuing licensing opportunities for its anti-fibrotic drug candidates. Revenue collapsed 99% to just $5,488 with cash reserves critically low at $330,000, though the company has a pending $3M transaction with XORTX Therapeutics for its VB4-P5 compound targeted to close by March 2026. Key points: Operating loss reduced by 33% to $731,694 through significant cost cutting measures; Operating costs cut from $1.5M to $0.7M in the half year; Binding term sheet signed with XORTX Therapeutics for $3M USD sale of VB4-P5 compound

Recent Announcements

26 Feb 2026 Actual Results Negative

Half Year Report & Appendix 4D

Vectus Biosystems reported a reduced half-year loss of $731,694 (down 33% from $1.1M previously) as the biotech company significantly cut operating costs while pursuing licensing opportunities for its anti-fibrotic drug candidates. Revenue collapsed 99% to just $5,488 with cash reserves critically low at $330,000, though the company has a pending $3M transaction with XORTX Therapeutics for its VB4-P5 compound targeted to close by March 2026. Key points: Operating loss reduced by 33% to $731,694 through significant cost cutting measures; Operating costs cut from $1.5M to $0.7M in the half year; Binding term sheet signed with XORTX Therapeutics for $3M USD sale of VB4-P5 compound

Get real-time alerts for VBS

Receive AI-powered earnings summaries and instant notifications when Vectus Biosystems Limited releases results.

Register Free